MDX-1097

MDX-1097 (formerly called IST-1097, now called KappaMab) is a monoclonal antibody therapy being developed by the Australian biotechnology company HaemaLogiX Ltd for the treatment of multiple myeloma.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

MDX-1097 (formerly called IST-1097, now called KappaMab) is a monoclonal antibody therapy being developed by the Australian biotechnology company HaemaLogiX Ltd for the treatment of multiple myeloma. In 2023, results were reported from a Phase IIb trial (AMaRC 01-16) assessing KappaMab alone and in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory kappa light chain-restricted multiple myeloma, a type of white blood cell cancer.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1377198786 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

6 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.